Why Use Fluconazole Treatment

One of the nastiest types of infection is fungal infection.  Although they are more likely to grow on the skin, there are more serious ones though that develops in the respiratory system and infect not just the lungs, but also the blood and other parts of the body’s internal structure.  When you develop a fungal infection, it is vital that you treat the infection as soon as possible to prevent further growth, development, and spread of the infection.  Failure to do so may mean longer and costlier treatment.  Fluconazole treatment is needed for treating fungal infection.  Fluconazole treatment is an antifungal medication treatment that you take orally.

Most antifungals are applied on the skin directly to where the infection has developed.  However, if the infection has buried further or deeper in to the skin, or the infection has developed inside of the body, such topical type of antifungal will not work on such.  For cases like this, fluconazole treatment is necessary as fluconazole treatment comes in pill form which you take orally.  The treatment process in using fluconazole treatment is the purging of the infection from the inside of your body.  This effectively gets rid of the infection from your system.

For antifungal fluconazole treatment, it is necessary that you use fluconazole treatment for a course of several days.  The number of days you need to use fluconazole treatment depends on the type of infection that you have developed and the severity that it has.  Course treatment is necessary in completely getting rid of an infection from the body.  This is the very reason why doctors prescribe patients with several days of use of fluconazole treatment when they have a fungal infection.  By completing the course of fluconazole treatment, you will be able to completely purge the fungal infection out of the body. Read more…

Mother of all studies claims half a million Britons

The world's biggest health study will shortly wind up recruiting, having today passed the 500,000 subject mark – persuading one in fifty Britons aged 40-69 to let researchers follow their health for the next 30 years.

The £66 million , backed by all the major institutions of British medical research, will "generate new knowledge about relationships between health, disease, genes and environment for many years to come", according to Sir Mark Walport, Director of the Wellcome Trust.

The study aims to be as deep as it is wide, with patients followed in considerable detail. Each has provided samples of blood, urine and saliva, and answered questionnaires on diet, exercise, family and personal history. Each has undergone a battery of tests including lung function, arterial stiffness, bone mineral density, grip strength, brain function, intraocular pressure, sight and hearing.

Much of the analysis won't be happening for at least a decade. But after that, organizers expect a steady stream of revelations in everything from cancer to heart disease to diabetes and arthritis. Needless to say, with their similar genetic heritage, many Canadians can expect Biobank will generate findings relevant to their lives. The study's ethical code dictates sharing anonymized data with all credible foreign researchers.

A key function of Biobank is to act as a gene database. As the NHS's reporting system picks up subjects' health woes, their samples will be analyzed to look for genetic correlations. But participants have been told they won't be getting any genetic analysis back. In fact, they don't stand to gain personally in any way. One striking feature of the study is that even if it detects evidence of illness in participants, whether through blood or urine samples, or because they have genes that turn out to be high-risk, Biobank won't inform the affected patients or their physicians.

One reason for this, the organizers say, is to stop insurance companies from penalising study volunteers. Insurance contracts often legally require purchasers to disclose test results they know, but not those they don't.

But a major ultimate goal of the Biobank is to find the links between DNA and diseases, and disseminate that knowledge as widely as possible. One suspects that at some point, the insurance companies are going to get involved in that process.

This morning, as they celebrated the recruiting of the half-millionth Biobank recruit, the great and the good of British medical research were effusive in their praise of these “local heroes” who will give so much of their time over the next 30 years for no obvious personal benefit. But hang on a minute – if they're all altruistic heroes, then how can they be a representative sample of the British population?

2 comments:

sharon (aka Purley Quirt) said...

'One striking feature of the study is that even if it detects evidence of illness in participants, whether through blood or urine samples, or because they have genes that turn out to be high-risk, Biobank won't inform the affected patients or their physicians.'

"situational ethics"... the hallmark of a declining civilization

said...

That's not the only shockingly lax part of the ethics of the UK Biobank study. I've blogged about it at http://dianthus.co.uk/uk-biobank.